Protein-nucleic acid aggregate for delivering biological preparation, and preparation method therefor
By designing the hollow structure of protein and nucleic acid agglutinates, the problem of low delivery efficiency of existing vectors is solved, efficient delivery and stability of biological agents are achieved, and the treatment effect of disease is improved.
Patent Information
- Application Number
- PCT/CN2023/092187
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-04
- Filing Date
- 2023-05-05
- Publication Date
- 2024-11-07
AI Technical Summary
Existing biological agent delivery vehicles such as liposomes and nanoparticles have problems such as limited drug loading, easy leakage and complex production processes, resulting in limited application of biological agents in disease treatment, especially the stability of polypeptides and proteins. Inefficient delivery of sexual and nucleic acid drugs.
A hollow carrier composed of protein and nucleic acid agglutinates was designed, and the hollow agglutinates were formed using histones and modified single-stranded nucleic acids. They interact with the cell membrane through electrostatic action to improve the delivery efficiency and stability of biological agents.
It realizes efficient delivery of biological agents, improves the efficiency of cell uptake of biological agents, improves the treatment effect of disease, and avoids the prone to coalescence and structural instability of non-hollow agglutinated structures.
Smart Images

Figure CN2023092187_07112024_PF_FP_ABST
Abstract
Description
A protein-nucleic acid aggregate for delivering biological agents and a preparation method thereof
[0001] This application claims priority to the prior Chinese application, application number: 202310490378.3, filing date May 4, 2023; all contents thereof are made part of the present invention. Technical Field
[0002] The present invention relates to the field of medicine, and in particular to a protein-nucleic acid aggregate for delivering biological agents and a preparation method thereof. Background Art
[0003] Biomacromolecules such as proteins and nucleic acids form membraneless organelles or aggregates through liquid-liquid phase separation (LLPS) mediated by weak multivalent interactions and conformational entropy. These aggregates participate in the regulation of numerous critical cellular processes and are closely associated with a variety of human diseases. LLPS-formed aggregates allow for the enrichment of biomolecules with distinct physicochemical properties while simultaneously isolating others. As separate intracellular compartments, aggregates create an isolated environment for the enriched molecules, thereby compartmentalizing and regulating intracellular biochemical reactions. The LLPS phenomenon is not limited to biological or pathological applications but also offers insights into biomimetic applications.
[0004] With the emergence of new biologics such as peptides, proteins, antibody drugs, nucleic acids, bacteria, and viruses, the requirements for delivery vehicles are constantly evolving. Limitations such as the stability of peptides and proteins, the susceptibility to degradation and low delivery efficiency of nucleic acid drugs, and the safety and immune clearance of viruses have restricted the application of new biologics in disease treatment. To address these challenges, traditional drug carriers such as liposomes and nanoparticles face limitations such as limited drug loading capacity, high leakage, and complex production processes. Therefore, the drug delivery field urgently needs new drug carriers to address the emerging challenges of biologics in disease treatment.
[0005] During their formation, aggregates can recruit biomacromolecules (peptides, proteins, etc.) into the compartments, effectively enriching guest molecules and retaining their biological activity, demonstrating their potential as delivery vehicles for biologics. However, the reversible and dynamic formation of aggregates by LLPS is not restricted by membrane structure and is prone to aggregation and is affected by environmental factors such as temperature, pH, and ionic strength, thus limiting their application in drug delivery.
[0006] This requires improving the existing delivery system and providing new carriers for delivering biological agents.
[0007] Summary of the Invention
[0008] The present invention designs and produces a novel delivery vector composed of hollow aggregates of proteins and nucleic acids. This structure offers the following advantages: excellent physiological stability and biocompatibility, enabling efficient recruitment of biologics and enhancing their cellular uptake, ultimately achieving effective delivery of biologics and improving disease treatment outcomes.
[0009] The present invention provides a delivery vector composed of a protein and nucleic acid agglomerate, wherein the vector is hollow or contains a space within the vector. This vector can be used to load biological agents, such as peptides, proteins, antibody drugs, nucleic acids, bacteria, and viruses, for the treatment or prevention of diseases, such as vaccines for infectious diseases and tumors.
[0010] Furthermore, the protein is a histone. In some embodiments, the histone is a mixture of multiple proteins. In some embodiments, the histone is derived from a calf thymus extract. In some embodiments, the histone includes any one or more of H1, H2A, H2B, H3, and H4.
[0011] In some embodiments, in addition to histones, non-histone sequence-specific DNA binding proteins may also be included.
[0012] The histones described in the present invention have the following characteristics: they are positively charged, contain Arg and Lys, are alkaline proteins, and are synthesized only during the S phase of the cell cycle. There are five types of histones: core histones H2A, H2B, H3, H4, and linker histone (H1). Histone structure is highly conserved, especially H4. The core histones consist of a globular portion and a tail. The globular portion uses electrostatic interactions between Arg and the phosphodiester backbone to wrap DNA molecules around the histone core, forming a nucleosome. The tail contains a large amount of Arg and Lys and is the site of post-translational modification. H1 is diverse and has genus and tissue specificity.
[0013] The non-histone sequence-specific DNA-binding protein described in this invention has the following characteristics: it is a negatively charged, acidic protein that is synthesized throughout the cell cycle and can recognize specific DNA sequences, binding via hydrogen and ionic bonds. Its functions include assisting DNA folding and replication and regulating gene expression.
[0014] The hollow aggregate formed by the present invention has a surface with positive charge or close to neutrality, and interacts with the negatively charged cell membrane; the hollow aggregate can maintain a stable structure under physiological conditions.
[0015] Furthermore, the nucleic acid is a modified single-stranded nucleic acid, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), or a mixture of DNA and RNA.
[0016] Furthermore, the modifying group includes substances similar to mammalian cell membranes.
[0017] In some ways, the modified group can be any one or more of cholesterol, phospholipids, glycolipids, and glycoproteins. The protein here can be a protein that constitutes the cell membrane. It is understandable that all molecules that constitute the cell membrane can be used to modify the single-stranded nucleic acid defined in the present invention, such as lipids, proteins, and a small amount of sugars, such as phospholipids, or substances similar to the components that constitute the cell membrane, such as amphiphilic substances, block copolymers, modified drugs, etc., can be used for modification. From a mechanistic point of view, all substances that are similar to cell membrane components can be used to modify single-stranded nucleic acids. For example, the cholesterol in one embodiment of the present invention is similar to the cell membrane component and can assist the transport of other components across the membrane.
[0018] In some embodiments, the modifying group is modified at the 3' end or 5' end of the single-stranded nucleic acid, or at both the 3' and 5' ends. Of course, it can also be modified at a position close to the end (modification at the 3' end or 5' end). Optionally, it can also be modified at the middle position of the single-stranded nucleic acid. The modification ratio is 0.1%-99%, which can be 1-95%, 1-85%, 1-75%, 1-55%, or 1-45%. The so-called ratio here refers to the substitution reaction of the modified purine base or pyrimidine base, ribose or deoxyribose, and phosphate functional groups in all the single-stranded nucleotides to carry out the modification of the present invention.
[0019] Furthermore, the cholesterol-modified single-stranded deoxyribonucleic acid can be any DNA fragment, with a length of approximately 5-1000 bp, preferably 10-500 bp, 15-300 bp, or 15-100 bp. The nucleotides can be composed of A, U, C, T, and G in any order (5'-adenylic acid, 5'-thymidylic acid, 5'-guanylic acid, 5'-inosinic acid, 3'-xanthylic acid, 5'-cytidylic acid, and 5'-uridylic acid), or can be composed entirely of single nucleotide molecules of A, U, C, T, and G for a certain length. For example, 5-AAAAAAAAAAAAAA-3, or 5-UUUUUUUUUUUUUUU-3, or 5-TTTTTTTTTTTTTTTTTTTTTT-3, or 5-CCCCCCCCCCCCCCCCCCCCCCCCCCCCC-3, or 5-GGGGGGGGGGGGGGGGGGGGGGGG-3. Of course, it can also be a single-stranded nucleotide composed of any of the above five base groups, such as 5-AAGGCCTTTTGTACTGGG-3, etc. The so-called single-stranded here refers to a nucleic acid that is mainly a single strand, and also includes a single-stranded nucleic acid with a hairpin structure. The single-stranded here is the opposite of the double-stranded.
[0020] Furthermore, the single-stranded nucleic acid is artificially synthesized or extracted from plants, animals, humans, or lower organisms.
[0021] Furthermore, the molar ratio of the histone to the modified single-stranded nucleic acid is 1:500 to 1:20.
[0022] Furthermore, the histone and modified single-stranded nucleic acid are mixed at a concentration ratio of 1 μM-50 μM ssDNA and 0.25 mM-2 mM histone. In some embodiments, the final concentration of the histone is 0.5 mM, and the final concentration of the modified single-stranded nucleic acid ssDNA is 10 μM.
[0023] Furthermore, the carrier includes a biological agent that can be delivered by the carrier, and the biological agent includes one or more of polypeptides, proteins, antibody drugs, nucleic acids, bacteria, and viruses.
[0024] Furthermore, the vector is formed by condensation of histones and modified single-stranded nucleic acids.
[0025] In another aspect, the present invention provides a method for preparing a hollow protein-nucleic acid aggregate carrier, comprising mixing histones with a modified single-stranded nucleic acid and a solvent, wherein the carrier has a hollow structure. In some embodiments, the molar ratio of the histones to the modified single-stranded nucleic acid is 1:500 to 1:20.
[0026] Furthermore, the solvent used in the preparation step is any one or more of PBS solution, citric acid-sodium citrate buffer solution, and disodium hydrogen phosphate-sodium dihydrogen phosphate buffer solution.
[0027] In some embodiments, the solvent is 1XPBS, with a pH of 7.4; or 0.1-0.01 M citric acid-sodium citrate buffer, with a pH of 5-6.5; or 0.1-0.01 M disodium hydrogen phosphate-sodium dihydrogen phosphate buffer, with a pH of 6.5-8.
[0028] Furthermore, the histone is mixed with a biological agent to be delivered, and then mixed with the modified single-stranded nucleic acid.
[0029] Furthermore, the biological agent includes one or more of: polypeptides, proteins, antibody drugs, nucleic acids, bacteria, and viruses.
[0030] Furthermore, the final concentration of the modified single-stranded nucleic acid is 0.1 μM to 50 μM, and the final concentration of histone is 0.025 mM to 2 mM.
[0031] In some methods, ssDNA with 5'-end modified cholesterol is mixed at a final concentration of 10 μM with a final concentration of 0.5 mM histone and 2.25*10 7 The virus molecules selectively accumulate in the phase-separated regions of the hollow aggregates through molecular enrichment via phase separation, forming adenovirus-encapsulated aggregates. The adenovirus-encapsulated aggregate preparations were subcutaneously injected to treat tumors in mice.
[0032] In another aspect, the present invention provides use of a hollow protein-nucleic acid aggregate carrier for preparing a delivery vector for delivering a biological agent to an organism.
[0033] In another aspect, the present invention provides a use of a hollow protein-nucleic acid aggregate vector encapsulating adenovirus for preparing a preparation for improving the therapeutic effect of tumors.
[0034] On the other hand, the present invention provides the use of modified single-stranded nucleic acids for preparing hollow protein-nucleic acid aggregate carriers. In some embodiments, the modified groups are one or more of cholesterol, phospholipids, glycolipids, and glycoproteins.
[0035] In some embodiments, the modification may be cholesterol modification or modification of substances similar to cell membranes, including phospholipids, proteins, and the like.
[0036] Furthermore, the modifying group is cholesterol.
[0037] The hollow protein-nucleic acid aggregate provided by the present invention has the following beneficial effects:
[0038] (1) It is clarified that the necessary condition for the generation of hollow aggregates is a modified single-stranded nucleic acid, which is modified into a molecule similar to the components of biological cell membranes. The modified single-stranded nucleic acid is not restricted, and there are many choices of modifiable molecules and optional modification methods, which has a wide range of applications.
[0039] (2) The concentration ratio of histones and modified single-stranded nucleic acids required to produce hollow aggregates was clarified. Hollow aggregates can be stably formed within the concentration range provided by the present invention. The highest proportion of hollow aggregates can be obtained at the optimal concentration ratio of the two.
[0040] (3) The hollow aggregate carriers formed have a stable structure in the physiological environment and high biocompatibility. They can efficiently recruit biological agents and improve the efficiency of cell uptake of biological agents, thus achieving effective delivery and assisting disease treatment. The formation of hollow aggregates avoids the problems of non-hollow aggregates that are too large, easy to aggregate, poor structural stability, irregular structure, and too large size, which lead to low delivery efficiency.
[0041] (4) The biopharmaceuticals that can be delivered include peptides, proteins, antibody drugs, nucleic acids, bacteria, viruses, etc., and have a wide range of applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figures 1(a)-(c) are phase diagrams and phase forms of liquid-liquid phase separation between proteins and nucleic acids in Example 1 of the present invention.
[0043] Figure 1(a) shows the morphology of aggregates and hollow aggregates formed by LLPS of rhodamine B-labeled histones and 6-FAM-labeled modified single-stranded ssDNA under a confocal microscope; the scale bar is 10 μm.
[0044] Figure 1(b) is a partial phase diagram between histones and ssDNA. It can be seen from Figure 1(b) that the ratio of the two is critical, and only when it is within a certain range can a hollow structure be obtained.
[0045] Figure 1(c) shows the potential diagram obtained by mixing histones and ssDNA at different ratios.
[0046] Figure 1(d) shows the structural formula of cholesterol modified at the 3' end of single-stranded deoxyribonucleic acid.
[0047] Figure 1(e) shows the structural formula of cholesterol modified on the 5' end of single-stranded deoxyribonucleic acid.
[0048] FIG2 is a phase diagram and phase form of liquid-liquid phase separation between histone and unmodified cholesterol single-stranded deoxyribonucleic acid (5'-AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-3') in Example 2 of the present invention.
[0049] Figure 2 (a) shows a partial phase diagram of histones and uncholesterol-modified single-stranded deoxyribonucleic acid. (b) shows a mixed solution of histones and Cy5-labeled nucleic acids. (c) shows an aggregate formed by LLPS of histones and nucleic acids labeled with the cyanine dye Cy5 (red). (d) shows an aggregate formed by LLPS of histones and Cy5-labeled nucleic acids. Scale bar: 50 μm. Uncholesterol-modified single-stranded deoxyribonucleic acid and histones cannot form hollow aggregate structures under the conditions described in Figure a.
[0050] Figure 3 illustrates the structure and morphology of aggregates and hollow aggregates in an embodiment of the present invention. (a, d) are three-dimensional confocal microscopy images of aggregates and hollow aggregates, respectively. (b, e) are scanning electron microscopy images of aggregate droplets and hollow aggregates, respectively. (c, f) are cryo-transmission electron microscopy images of aggregate droplets and hollow aggregates, respectively.
[0051] Figure 4 shows the performance of assemblies formed during the LLPS process according to an embodiment of the present invention. (a) shows the fusion phenomenon of aggregate droplets. (b) shows a series of confocal microscopy images of fluorescence recovery after photobleaching of aggregate droplets and fluorescence intensity analysis. (c) shows a series of confocal microscopy images of fluorescence recovery after photobleaching of hollow aggregates and fluorescence intensity analysis. Scale bar: 5 μm.
[0052] Figure 5 shows the phase diagrams and phase forms of virus loading based on liquid-liquid phase separation between proteins and nucleic acids in an embodiment of the present invention. (a) shows the morphology of aggregates and hollow aggregates formed by LLPS of rhodamine B-labeled histones, 6-FAM-labeled ssDNA, and Cy5 (blue)-labeled adenovirus ad11 (Cy5-ad11) under a confocal microscope. Scale bar: 10 μm. (b) shows a partial phase diagram of the three.
[0053] Figure 6 illustrates the enrichment of biological agents by aggregate droplets and hollow aggregates according to an embodiment of the present invention. Figure 6(a) shows fluorescence intensity analysis of histones, ssDNA, and the Ad11 virus (scale bar = 5 μm). Figure 6(b) compares the loading efficiency of the Ad11 virus in aggregates and hollow aggregates.
[0054] Figure 7 shows the distribution of viruses in phase-separated systems according to an embodiment of the present invention. (a) is a transmission electron microscopy image of a single virus. (b) is a transmission electron microscopy image of a virus in a protein-nucleic acid solution. (c) is a cryo-transmission electron microscopy image of a virus within a protein-nucleic acid aggregate droplet. (d) is a cryo-transmission electron microscopy image of a virus within a hollow protein-nucleic acid aggregate. Scale bar: 100 nm.
[0055] Figure 8 shows the structural stability of aggregate droplets and hollow aggregates in an embodiment of the present invention. (a) shows the turbidity and morphology changes of aggregate droplets and hollow aggregates at the initial time and after 48 hours. (b) shows the particle size changes of aggregate droplets and hollow aggregates at the initial time and after 48 hours. The scale bar is 10 μm. As shown in Figure 8(b), the particle size of the hollow aggregates changes little, remaining essentially unchanged after 48 hours (the two bar graphs on the left of Figure 8(b)). In contrast, the particle size of the aggregate droplets changes significantly, from approximately 2321 nm to 8619 nm (the two bar graphs on the right of Figure 8(b)).
[0056] Figure 9A shows the viral uptake of aggregate droplets and hollow aggregates as viral vectors in mouse lung epithelial cells (TC-1) and a TC-1 cell line that overexpresses the CD46 receptor, according to an embodiment of the present invention. (a) shows the uptake and viral content of Ad11 or Ad11 solution, Ad11 / aggregates, and Ad11 / hollow aggregates in the TC-1 cell line. (b) shows the uptake and viral content of Ad11 or Ad11 solution, Ad11 / aggregates, and Ad11 / hollow aggregates in the TC-1 cell line that overexpresses CD46. Scale bar: 20 μm.
[0057] In Figure 9B, 1 represents the virus alone (ad11), 2 represents the virus solution alone (ad11 solution), 3 represents the aggregate / virus (ad11 / aggregate) (non-hollow); 4 represents the hollow aggregate / virus (ad11 / hollow aggregate), indicating that the hollow one loaded with virus is more stable and has the highest number of viruses taken up by cells, which is significantly different from the non-hollow one (after normalization, when the number of the pure virus group is 1, the ad11 / solution is approximately 3, the ad11 / aggregate is approximately 5, and the ad11 / hollow aggregate has a loading capacity of approximately 7).
[0058] Figure 10 shows the accumulation of ad11 in tumor tissue according to an embodiment of the present invention. The scale bar is 100 μm.
[0059] Figure 11 shows the in vivo efficacy data of the present invention in the TC-1 mouse tumor model. (a) shows the actual tumors in each group of mice after 10 days of treatment. (b) shows the tumor weights in each group of mice after 10 days of treatment. (c) shows the average tumor growth curves in each group of mice after treatment. As can be seen from the figure, the size of small tumors treated with ad11 / hollow aggregates remained essentially unchanged, while the size of tumors in the other treatments (PBS, hollow aggregates alone, virus treatment alone, and non-hollow aggregates) increased rapidly within 12 days, showing a highly significant difference from the size of small tumors treated with ad11 / hollow aggregates. Figure 11B also shows a significant change in weight after 10 days. The weight of the ad11 / hollow aggregates was approximately 0.5 g, while the weights of the PBS, hollow aggregates alone, virus treatment alone, and non-hollow aggregates were approximately 2.4 g, 2.3 g, 1.9 g, and 1.8 g, respectively, showing significant or highly significant differences from these treatments. DETAILED DESCRIPTION
[0060] The present invention will be described in further detail below in conjunction with the accompanying drawings and Examples. It should be noted that the following examples are intended to facilitate understanding of the present invention and do not serve to limit the present invention in any way. The reagents used in this example are all known products and were obtained by purchasing commercially available products.
[0061] Example 1: Histones and modified single-stranded nucleic acids form hollow aggregates.
[0062] Different concentrations of rhodamine B-labeled histone (Histone) (purchased from Sangon Biotech (Shanghai) Co., Ltd., product number A002544) and 6-carboxyfluorescein (6-FAM)-labeled cholesterol-modified ssDNA (5'-Cholestery-AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-6-FAM-3' (SEQ NO: 1)) were prepared and mixed to final Histone concentrations of 2 mM, 1 mM, 0.5 mM, 0.25 mM, 0.1 mM, 0.05 mM, and 0.025 mM, and final ssDNA concentrations of 50 μM, 25 μM, 10 μM, 5 μM, 1 μM, 0.5 μM, and 0.1 μM. The solvent was 1X PBS (pH 7.4). Figure 1(b) shows the phase diagram under corresponding conditions, which was drawn by observing the morphology of the phases in the system under a laser confocal microscope. As the concentrations of the two and the potential in the system change, three phase forms are displayed: a uniform solution, a droplet-shaped aggregate (non-hollow), and a hollow aggregate. Experiments have found that cholesterol modification at the 5' or 3' end of single-stranded deoxyribonucleic acid (Figure 1(d) shows the structural formula of cholesterol modification at the 3' end of single-stranded deoxyribonucleic acid, and Figure 1(e) shows the structural formula of cholesterol modification at the 5' end of single-stranded deoxyribonucleic acid) can form the above-mentioned phase-separated assemblies.
[0063] The conditions for forming hollow aggregates were 1 μM-50 μM ssDNA mixed with 0.25 mM-2 mM histones. The highest proportion of hollow aggregates was achieved when the final concentrations of histones were 0.5 mM and ssDNA were 10 μM.
[0064] It is understood that, in addition to the specific method described in Example 1 of this embodiment, other modifications besides cholesterol are also feasible. For example, phospholipids, proteins, and other substances similar to the composition of cell membranes can be used to modify nucleic acids. Our experiments have shown that hollow aggregates can be obtained. In addition, the nucleic acid can be any single-stranded nucleic acid substance, such as DNA, RNA, etc. These nucleic acid substances can be artificially synthesized or extracted from plants, animals, humans, or lower organisms. The length of these single-stranded nucleic acids can be any length, generally less than 1000 bp, less than 500 bp, less than 100 bp, or between 10-80 bp. In other methods, these single-stranded nucleic acids can be a mixture of one or more different sequences and lengths, but all single-stranded nucleic acids need to be modified. The modification location can be at either end of the nucleic acid, such as the 5' or 3' end, or both the 5' and 3' ends, or near the end of the nucleic acid, such as a position 10-1 nucleotides away from the 5' or 3' end. This can be arbitrarily selected through the disclosure of the present invention, such as modifying the middle position of the nucleic acid. Through our experiments, the above selections and combinations can also obtain hollow aggregates.
[0065] Example 2: Histones and unmodified single-stranded nucleotides cannot form hollow aggregates
[0066] As shown in Figure 2, solutions of different concentrations of Histone (the same as in Example 1) and ssDNA labeled with cyanine dye Cy5 (sequence 5'-AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-Cy5-3') were prepared respectively, and the two solutions were mixed to a final concentration of Histone of 2mM, 1mM, 0.5mM, 0.25mM, 0.1mM, 0.05mM, 0.025mM, and a final concentration of ssDNA of 50μM, 25μM, 10μM, 5μM, 1μM, 0.5μM, 0.1μM. The morphology of the phase in the system was observed under a fluorescence microscope to draw a phase diagram under the corresponding conditions. As the concentration and ratio of the two changed, three forms of phases were exhibited: a uniform solution, a droplet-shaped aggregate, and an aggregate. Unmodified cholesterol ssDNA and histones failed to obtain hollow aggregates under this condition.
[0067] This experiment shows that single-stranded nucleic acids must be modified to form a hollow structure, and without modification, a hollow structure cannot be formed. As for the modification ratio and the concentration ratio with histones, they can all be adjusted through experiments.
[0068] Example 3: Characterization of the structure and morphology of aggregates and hollow aggregates in the examples of the present invention
[0069] As shown in Figure 3, aggregates were prepared at a final histone concentration of 0.25 mM and a final ssDNA concentration of 50 μM, while hollow aggregates were prepared at a final histone concentration of 0.5 mM and a final ssDNA concentration of 10 μM. Characterization using confocal microscopy, scanning electron microscopy, and cryo-transmission electron microscopy demonstrated that the aggregate droplets were solid spheres, while the hollow aggregates contained an aqueous phase. The hollow spherical structure obtained by phase separation (as described in the text of Figure 3d) was the same as in Example 1. The specific histones and modified single-stranded nucleic acids were the same as those in Example 1.
[0070] Example 4: Performance Characterization of the Assembly Formed by the LLPS Process in the Example of the Present Invention
[0071] As shown in Figure 4, aggregates were prepared at a final histone concentration of 0.25 mM and a final ssDNA concentration of 50 μM, while hollow aggregates were prepared at a final histone concentration of 0.5 mM and a final ssDNA concentration of 10 μM (the specific histones and modified single-stranded nucleic acids were the same as in Example 1). The structures assembled by phase separation possess characteristics of liquid systems, such as molecular mobility and deformability. Adjacent droplets fuse after contact (0 s). After fusion (180 s), the droplets tend to form a spherical structure under the action of surface tension, confirming that protein-nucleic acid phase separation occurs. In addition, fluorescence recovery after photobleaching experiments can be used to prove that the assembly is formed by the LLPS process. Specific areas of the aggregate droplets and hollow aggregates (white arrows) are photobleached (50% light intensity, photobleaching time of 10 s), and then the fluorescence recovery is measured. Confocal microscopy images showed a gradual recovery of fluorescence in the bleached regions of both assemblies. The fluorescence of the aggregates recovered almost completely after 60 seconds, while that of the hollow aggregates recovered to 60% after 1200 seconds. This demonstrates that both phase-separated assemblies exhibit liquid-like molecular mobility, with the aggregates exhibiting greater molecular mobility. This is a disadvantage in later applications, as high mobility can lead to poor structural stability, limiting subsequent applications. In contrast, the hollow aggregates exhibit low mobility and a stable structure, facilitating the subsequent delivery of practical biological agents.
[0072] Example 5: Phase diagram and phase form of virus loading based on liquid-liquid phase separation between protein and nucleic acid in the example of the present invention.
[0073] As shown in Figure 5, solutions of rhodamine B-labeled histone (Histone) and 6-carboxyfluorescein (6-FAM)-labeled cholesterol-modified ssDNA (5'-Cholestery-AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-6-FAM-3') with different concentrations were prepared respectively. The two solutions were mixed to a final concentration of Histone of 2mM, 1mM, 0.5mM, 0.25mM, 0.1mM, 0.05mM, and 0.025mM, and a final concentration of ssDNA of 50μM, 25μM, 10μM, 5μM, 1μM, 0.5μM, and 0.1μM. Before mixing histone and ssDNA, 2.25*10 7 A mixture of pfu of Cy5-labeled adenovirus (Cy5-ad11) (Cy5-ad11 was a gift from Beijing Bio-Targeting Therapeutics Technology Co., Ltd. (Beijing, China)) (plaque forming unit, abbreviated as pfu) was performed. Histones and modified single-stranded nucleic acids recruited Cy5-ad11 to the assembled compartments during phase separation. Compared to systems containing only proteins and nucleic acids, the Cy5-ad11-added system also exhibited three forms: a homogeneous solution, droplet-like aggregates, and hollow aggregates.
[0074] Our experiments have shown that mixing the same adenovirus with modified nucleic acid and then with histones yields three distinct forms: a uniform solution, droplet-like aggregates, and hollow aggregates. However, the efficiency of producing hollow aggregates is lower when mixing adenovirus with histones.
[0075] Example 6: Enrichment of biological agents by aggregate droplets and hollow aggregates in the embodiments of the present invention
[0076] As shown in Figure 6(a), aggregates were prepared under the conditions of a final histone concentration of 0.25 mM and a final ssDNA concentration of 50 μM, and hollow aggregates were prepared under the conditions of a final histone concentration of 0.5 mM and a final ssDNA concentration of 10 μM. The total volume of each system was 40 μL, and the number of Cy5-ad11 was 9*10 7pfu. The phase separation system has excellent molecular enrichment ability, which promotes the efficient loading of biological agents. The analysis of the fluorescence intensity and distance distribution of histones, ssDNA and viruses confirmed the effective enrichment of viruses by the phase separation domain (scale bar is 5 microns). The analysis software is Image J. Two assemblies for enriching viruses were prepared under the conditions of a final histone concentration of 0.25mM and a final ssDNA concentration of 50μM, and under the conditions of a final histone concentration of 0.5mM and a final ssDNA concentration of 10μM. The real-time fluorescence quantitative technology was used to calculate the virus loading rate of the two assemblies. The loading rate of the aggregates was 92.8%, and that of the hollow aggregates was 81.4%, as shown in Figure 6(b).
[0077] Example 7: Distribution of viruses in a phase separation system in an example of the present invention.
[0078] As shown in Figure 7, a solution was obtained under the conditions of a final histone concentration of 0.5 mM and a final ssDNA concentration of 0.1 μM; an aggregate was prepared under the conditions of a final histone concentration of 0.25 mM and a final ssDNA concentration of 50 μM; a hollow aggregate was prepared under the conditions of a final histone concentration of 0.5 mM and a final ssDNA concentration of 10 μM; the total volume of each system was 40 μL, and the number of Cy5-ad11 was 9*10 7 pfu. The viruses in the solution are clustered together (Figure 7b). Through molecular enrichment via phase separation, the viruses are isolated from the external environment by being segregated within the aggregate droplets and hollow aggregates. As shown in Figure 7(c), within the aggregates, the viruses are evenly dispersed within the aggregate droplets. As shown in Figure 7(d), within the hollow aggregates, the viruses are selectively enriched in the phase-separated region of the hollow aggregates, distributed within the annular region and co-localized with histones and single-stranded nucleic acids.
[0079] Example 8: Study on the structural stability of aggregate droplets and hollow aggregates in the embodiments of the present invention
[0080] As shown in Figure 8 , aggregates were prepared at a final histone concentration of 0.25 mM and a final ssDNA concentration of 50 μM, while hollow aggregates were prepared at a final histone concentration of 0.5 mM and a final ssDNA concentration of 10 μM. Compared to hollow aggregates (A in Figure 8(b)), the droplets of aggregates (non-hollow, Figure 8(b) B) possess greater fluidity and deformability, resulting in a tendency for aggregate droplets to coalesce over time. This characteristic is reflected in the gradual decrease in turbidity of the aggregate system, the aggregation of aggregates, and a significant increase in particle size. Due to the poor structural stability, irregular structure, and excessive size of the aggregates, the efficiency of subsequent aggregate delivery of viruses to tumor cells is reduced, thereby affecting the efficacy of tumor treatment. In contrast, the fluidity and deformability of hollow aggregates or carrier droplets are weaker than those of non-hollow ones, resulting in the fact that hollow aggregates do not coalesce over time. As a result, the structure is more stable, more regular, and of the appropriate size, enabling the delivery of the desired substance into cells.
[0081] Example 9: Viral uptake of aggregate droplets and hollow aggregates as viral vectors in mouse lung epithelial cells (TC-1) and TC-1 cell lines that highly express the receptor CD46
[0082] As shown in Figure 9, aggregates were prepared under the conditions of a final histone concentration of 0.25 mM and a final ssDNA concentration of 50 μM, and hollow aggregates were prepared under the conditions of a final histone concentration of 0.5 mM and a final ssDNA concentration of 10 μM. The number of Cy5-ad11 (adenovirus) was 1*10 7 pfu. The above solution was added to mouse lung epithelial cells (TC-1) and TC-1 cell lines that highly express the receptor CD46. The cell number was 500,000 and the virus number was 20 pfu per cell. The above system was incubated in a cell culture incubator at 37°C and 5% CO2 for 4 hours to remove free viruses / assemblies. Through the process of staining the cytoskeleton with phalloidin and the cell nucleus with Hoechst 33342 and observation under laser confocal microscopy, it was confirmed that the uptake efficiency of adenovirus ad11 labeled with Cy5 using hollow aggregates as carriers was significantly improved. The above conclusion was also verified by measuring the content of intracellular viruses using real-time fluorescence quantitative technology.
[0083] Example 10: Accumulation of ad11 in tumor tissues according to the present invention (scale bar: 100 μm)
[0084] Aggregates were prepared under the conditions of a final histone concentration of 0.25 mM and a final ssDNA concentration of 50 μM, and hollow aggregates were prepared under the conditions of a final histone concentration of 0.5 mM and a final ssDNA concentration of 10 μM. As shown in Figure 10, untreated TC-1 cells were cultured, and the number of subcutaneous tumor-bearing cells was 2*10 6 Inject 100 μL to establish the animal model. C57 / BL-6J, 8-week-old female mice were selected for the experiment. The experimental mice were raised until the tumor size reached 100 mm. 3 The preparations were injected intratumorally. The preparations included: PBS group, ad11 group, ad11 / aggregate group, and ad11 / hollow aggregate group. The PBS group served as the control group and received an intratumoral injection of 50 μL 1X PBS (pH 7.4); the ad11 group served as the virus-only group and received an intratumoral injection of 50 μL of virus, with a viral load of 1*10 8 pfu; ad11 / aggregate group composition: histone final concentration was 0.25 mM, ssDNA final concentration was 50 μM, and the number of viruses was 1*10 8 pfu, the intratumoral injection dose was 50 μL; ad11 / hollow aggregate group composition: the final histone concentration was 0.5 mM, the final ssDNA concentration was 10 μM, and the virus number was 1*10 8 pfu, and the intratumoral injection dose was 50 μL. The virus was labeled with Cy5 fluorescence, and the frozen sections of the tumor tissue were stained with DAPI.
[0085] Images of tumor tissue sections captured using a fluorescence microscope confirmed the hollow aggregates' superior delivery capabilities as biological agent delivery vehicles, enhancing cellular viral uptake. Specifically, the Cy5 fluorescence intensity in tumor tissue treated with ad11 / hollow aggregates was higher than in other groups, indicating an increase in viral load within the tumor tissue. The oncolytic virus replicated and proliferated in tumor cells, ultimately causing tumor cell lysis and the release of more oncolytic virus, leading to tumor lysis and enhanced anti-tumor efficacy.
[0086] Example 11: In vivo efficacy data of the present invention in the TC-1 mouse tumor model
[0087] Aggregates were prepared under the conditions of a final histone concentration of 0.25 mM and a final ssDNA concentration of 50 μM, and hollow aggregates were prepared under the conditions of a final histone concentration of 0.5 mM and a final ssDNA concentration of 10 μM. As shown in Figure 10, untreated TC-1 cells were cultured, and the number of subcutaneous tumor-bearing cells was 2*10 6 Inject 100 μL to establish the animal model. C57 / BL-6J, 8-week-old female mice were selected for the experiment. The experimental mice were raised until the tumor size reached 100 mm. 3The preparations were injected intratumorally. The preparations included: PBS group, ad11 group, ad11 / aggregate group, and ad11 / hollow aggregate group. The PBS group served as the control group and received an intratumoral injection of 50 μL 1XPBS (pH 7.4); the ad11 group served as the virus-only group and received an intratumoral injection of 50 μL of virus, with a viral load of 1*10 8 pfu; ad11 / aggregate group composition: histone final concentration was 0.25 mM, ssDNA final concentration was 50 μM, and the number of viruses was 1*10 8 pfu, the intratumoral injection dose was 50 μL; ad11 / hollow aggregate group composition: the final histone concentration was 0.5 mM, the final ssDNA concentration was 10 μM, and the virus number was 1*10 8 pfu, with an intratumoral injection dose of 50 μL. The formulation was injected every two days, and tumor size was recorded. In vivo efficacy experiments confirmed that hollow aggregates significantly enhanced the antitumor efficacy of the virus. In the TC-1 mouse tumor model, tumor volume was significantly suppressed after administration, demonstrating that hollow aggregates as viral delivery vehicles can significantly improve therapeutic efficacy. As shown in Figure 11, using hollow aggregates to deliver antitumor drugs significantly inhibited tumor volume and weight increases, demonstrating a highly significant difference compared to aggregates loaded with the same antitumor drug.
[0088] All patents and publications cited in this specification are intended to indicate that they are state of the art and that the present invention may be used. All patents and publications cited herein are incorporated by reference in their entirety, as if each publication were specifically incorporated by reference. The invention described herein may be practiced in the absence of any element or elements, limitation or limitations, unless otherwise specified. For example, in each instance, the terms "comprising," "consisting essentially of," and "consisting of" may be replaced with either of the other two terms. The term "a" or "an" herein simply means "one" and does not exclude the inclusion of only one or more. The terms and expressions used herein are intended to be descriptive, not limiting, and are not intended to exclude any equivalent features. However, it is understood that any suitable changes or modifications may be made within the scope of the present invention and the appended claims. It is understood that the embodiments described herein are preferred embodiments and features, and that modifications and variations can be made by persons of ordinary skill in the art based on the spirit of the present invention. Such modifications and variations are considered to be within the scope of the present invention and the scope of the independent and appended claims.
Claims
1. A carrier, It is characterized in that The carrier comprises histone and single-stranded nucleic acid modified by groups, wherein the carrier is a hollow structure.
2. The vector according to claim 1, It is characterized in that The modifying groups include substances similar to mammalian cell membranes.
3. The vector according to claim 2, It is characterized in that The modifying group is any one or more of lipids, proteins, carbohydrates, amphiphilic substances, block copolymers, and drugs.
4. The vector according to claim 3, It is characterized in that The modified group is any one or more of cholesterol, phospholipid, glycolipid and glycoprotein.
5. The vector according to claim 4, It is characterized in that The modifying group is cholesterol.
6. The vector according to claim 1, It is characterized in that The ratio of the group-modified single-stranded nucleic acid is 0.1%-99%. 7 . The vector according to claim 1 , wherein the molar ratio of the histone to the modified single-stranded nucleic acid is 1:500 to 1:
20.
8. The vector according to claim 1, It is characterized in that The position where the group modifies the single-stranded nucleic acid is at the 3' end or 5' end of the single-stranded nucleic acid, or at a position close to the 3' end or 5' end, or at a position in the middle of the nucleic acid.
9. The vector according to claim 1, It is characterized in that The single-stranded nucleic acid is DNA and / or RNA.
10. The vector according to claim 1, It is characterized in that Single-stranded nucleic acid consists of A, U, C, T, and G in any order.
11. The vector according to claim 10, It is characterized in that The single-stranded nucleic acid is artificially synthesized or extracted from plants, animals, humans, and lower organisms.
12. The vector according to claim 1, It is characterized in that The length of the single-stranded nucleic acid is less than 1000 bp.
13. The vector according to claim 12, It is characterized in that The length of the single-stranded nucleic acid is less than 500 bp, or less than 100 bp, or 10-80 bp.
14. The vector according to claim 1, It is characterized in that The histones include any one or more of H1, H2A, H2B, H3 and H4.
15. The vector according to claim 14, It is characterized in that In addition to histones, non-histone sequence-specific DNA binding proteins may also be included.
16. The vector according to claim 1, It is characterized in that The final concentration of the modified single-stranded nucleic acid is 0.1 μM to 50 μM, and the final concentration of histone is 0.025 mM to 2 mM.
17. The vector according to claim 16, It is characterized in that The final concentration of the modified single-stranded nucleic acid was 10 μM, and the final concentration of histone was 0.5 mM.
18. The vector according to claim 1, wherein the vector comprises a biological agent that can be delivered by the vector, and the biological agent comprises one or more of polypeptides, proteins, antibody drugs, nucleic acids, bacteria, and viruses. The vector according to claim 1 , wherein the vector is formed by condensation of histone and modified single-stranded nucleic acid.
20. A method for preparing a hollow carrier: It is characterized in that The method is prepared by mixing histone, modified single-stranded nucleic acid and solvent, and the carrier is a hollow structure.
21. The method according to claim 20, It is characterized in that The solvent is any one or more of PBS solution, citric acid-sodium citrate buffer solution, disodium hydrogen phosphate-sodium dihydrogen phosphate buffer solution.
22. The method according to claim 20, It is characterized in that The histone is mixed with a biological agent to be delivered and then mixed with the modified single-stranded nucleic acid.
23. The method according to claim 22, It is characterized in that The biological agents include: one or more of polypeptides, proteins, antibody drugs, nucleic acids, bacteria, and viruses.
24. The method according to claim 20, It is characterized in that The final concentration of the modified single-stranded nucleic acid is 0.1 μM to 50 μM, and the final concentration of histone is 0.025 mM to 2 mM.
25. Use of the hollow protein-nucleic acid aggregate carrier according to any one of claims 1 to 15 for preparing a delivery carrier, It is characterized in that The delivery vector is used to deliver a biological agent to an organism.
26. Use of the hollow protein-nucleic acid aggregate carrier encapsulated adenovirus as claimed in any one of claims 1 to 15 for preparing a preparation for improving the therapeutic effect of tumors.
27. Use of modified single-stranded nucleic acid for preparing hollow protein-nucleic acid condensate carriers, It is characterized in that The modified group is one or more of cholesterol, phospholipid, glycolipid and glycoprotein.
28. The use according to claim 27, wherein the modifying group is cholesterol.
Citation Information
Patent Citations
Designer membraneless organelles sequester native factors for control of cell behavior
WO2023015190A1
